Dr. Raj Satkunasivam on MIBC Neoadjuvant Approaches for Local, Distant Control

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, explains how muscle-invasive bladder cancer (MIBC) is traditionally approached, the current momentum for an immunotherapy-plus-radiation strategy, and how previous research has led to the development and testing of the PD-1 monoclonal antibody sasanlimab in this setting.

Dr. Satkunasivam is the lead investigator of the RAD VACCINE MIBC trial, a phase 2 clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC.

View Dr. Satkunasivam’s further comments.